Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$46.15
+0.4%
$38.37
$21.72
$46.84
$8.77B1.152.52 million shs1.07 million shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+6.46%+7.35%+17.81%+42.31%+78.91%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
4.6879 of 5 stars
4.52.00.03.92.43.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
3.00
Buy$58.9327.69% Upside

Current Analyst Ratings Breakdown

Latest BBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$60.00
6/30/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$67.00 ➝ $76.00
6/25/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$50.00 ➝ $54.00
6/17/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$49.00
6/9/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$53.00 ➝ $56.00
4/30/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$46.00 ➝ $63.00
4/30/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$52.00 ➝ $55.00
4/30/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$65.00 ➝ $72.00
4/15/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$49.00 ➝ $53.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$127.42M68.78N/AN/A($7.71) per share-5.99
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$535.76M-$3.53N/AN/AN/A-524.25%N/A-94.43%7/30/2025 (Estimated)

Latest BBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.50N/AN/AN/AN/AN/A
4/29/2025Q1 2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$1.00-$0.88+$0.12-$0.88$57.14 million$36.74 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
4.57
4.54

Institutional Ownership

CompanyInstitutional Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%

Insider Ownership

CompanyInsider Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
18.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400189.88 million155.32 millionOptionable

Recent News About These Companies

Oppenheimer Upgrades BridgeBio Pharma (BBIO)
Leerink Partnrs Issues Negative Estimate for BBIO Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$46.15 +0.17 (+0.37%)
As of 12:29 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.